Abstract
In clinical trials, crossover from assigned control treatments onto other experimental treatments or alternatives often creates difficulties in estimating the underlying comparative efficacy and CE of experimental treatments. We examined the impact of adjusting crossover from everolimus to nivolumab in the third- or later-line treatment in the phase III CheckMate 025 trial on the estimated relative efficacy and CE of nivolumab in pre-treated patients with aRCC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
